Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
73.32 CHF | +1.13% | +3.12% | +11.70% |
Apr. 29 | Sector Update: Health Care Stocks Edge Higher Late Afternoon | MT |
Apr. 29 | Sight Sciences Says it Obtained $34 Million Patent Infringement Verdict Against Alcon -- Shares Jump | MT |
Evolution of the average Target Price on Alcon Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Alcon Inc.
UBS | |
Argus | |
Mizuho Securities | |
Needham & Co. | |
alphavalue | Abhishek Raval |
KeyBanc Capital Markets | |
Bernstein | |
Morgan Stanley | |
Jefferies & Co. | |
Berenberg Bank | |
Societe Generale | |
Wells Fargo Securities | |
Nephron Research | |
BNP Paribas Exane | |
Baird | |
JPMorgan Chase | |
Citigroup | |
BTIG | |
Credit Suisse | |
BNP Paribas | |
DA Davidson | |
Stephens Inc. | |
Goldman Sachs | |
Exane BNP | |
Oppenheimer | |
Kepler Capital Markets | |
SVB Leerink | |
Davy | |
Octagon Capital | |
JPMORGAN | James Gordon |
EPS Revisions
- Stock Market
- Equities
- ALC Stock
- Consensus Alcon Inc.